Submit to Special Issue Submit Abstract to Special Issue Review for IJMS Propose a Special Issue

Journal Menu

Journal Browser

Molecular Research and Treatment in Multiple Sclerosis

Print Special Issue Flyer
Special Issue Editors
Special Issue Information
Keywords
Benefits of Publishing in a Special Issue
Published Papers

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Biology".

Deadline for manuscript submissions: 20 October 2025 | Viewed by 5301

Share This Special Issue

Special Issue Editors

Dr. Nada Starčević Čizmarević

E-Mail Website
Guest Editor

Department of Medical Biology and Genetics, Faculty of Medicine, University of Rijeka, 51000 Rijeka, Croatia
Interests: human genetics; neurodegenerative diseases; multiple sclerosis; cytogenetics

Prof. Dr. Borut Peterlin

E-Mail Website
Guest Editor

Clinical Institute of Genomic Medicine, University Medical Center Ljubljana, SI-1000 Ljubljana, Slovenia
Interests: public health genomics; genomic medicine in health systems; mechanisms of human genetic and complex disorders
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Multiple sclerosis (MS) is a neurodegenerative disease of the central nervous system with autoimmune and inflammatory features. The precise etiology of MS remains elusive, presumed to result from complex interactions between genetic predispositions and environmental influences, infectious exposures, and factors that lead to pro-inflammatory conditions and neuronal injury. Despite extensive research on the development of new drugs, there is no effective therapy for all patients, and the response of patients to available medication varies greatly.

This Special Issue aims to expand knowledge and clarify the molecular mechanisms and genetic factors involved in multiple sclerosis in order to search for accurate biomarkers and contribute to advances in the treatment of all forms of MS.

This Special Issue only considers papers that use molecular data to improve our understanding of the genetic and molecular basis of the disease and to develop therapeutic strategies based on the underlying mechanisms of MS, neuroprotection, and repair.

Therefore, we invite researchers and clinicians to submit articles with their findings that address various aspects of MS, with a focus on molecular research and treatment strategies.

Dr. Nada Starčević Čizmarević
Dr. Borut Peterlin
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

multiple sclerosis
neuroinflammation
neurodegeneration
genetics
molecular research
biomarkers
neuroimaging
therapy

Benefits of Publishing in a Special Issue

Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (4 papers)

Download All Papers

Order results

Result details

Show export options Show export options

Select all

Export citation of selected articles as:

Research

17 pages, 712 KiB

Open AccessArticle

Association of Functional Gene Variants in DYSF–ZNF638, MTSS1 and Ferroptosis-Related Genes with Multiple Sclerosis Severity and Target Gene Expression

by Tamara Djuric, Ana Djordjevic, Jovana Kuveljic, Milan Stefanovic, Evica Dincic, Ana Kolakovic and Maja Zivkovic

Int. J. Mol. Sci. 2025, 26(11), 4986; https://doi.org/10.3390/ijms26114986 - 22 May 2025

Viewed by 96

Abstract

Multiple sclerosis (MS) is a chronic inflammatory, neurodegenerative disease with yet-unresolved mechanisms of progression. To address MS severity and neurological deficits, we analyzed seven potentially functional genetic variants and their haplotypes in 845 MS patients. Based on our previous results of targeted RNAseq on ferroptosis-related genes in distinctive MS phenotypes, we selected putative regulatory variants in the top three DEGs (CDKN1A, MAP1B and EGLN2) and investigated their association with gene expression, plasma/serum parameters and disease severity (EDSS, MSSS, gARMSS). The study included 604 patients with relapsing–remitting (RR) and 241 with progressive (P) MS. The variants CDKN1A rs3176326 and rs3176336, EGLN2 rs111833532, MAP1B rs62363242 and rs1217817 with the previously reported DYSF-ZNF638 locus rs10191329, and MTSS1 rs9643199 were genotyped using TaqMan^®, and the HLA-DRB1*15:01 status was also determined. Significant association of the rare MAP1B rs62363242 allele with PMS in females, independent of HLA-DRB1*1501, was found. The A allele-containing genotypes were associated with molecular components of iron metabolism. CDKN1A haplotypes were significantly associated with CDKN1A mRNA levels in RRMS and SPMS patients. RAB4B-EGLN2 locus rs111833532 and DYSF-ZNF638 locus rs10191329 showed significant associations with EDSS, MSSS and gARMSS. We detected haplotypes associated with the expression of CDKN1A, a part of the p53-p21 axis known to affect T cell activation/proliferation. RAB4B-EGLN2, an oxygen sensor and critical regulator of the response to hypoxia, variant rs111833532, along with DYSF-ZNF638 locus rs10191329, was associated with clinical severity. The indicated, novel, sex-specific association of MAP1B rs62363242 with the course of MS remains to be validated in larger studies. Full article

(This article belongs to the Special Issue Molecular Research and Treatment in Multiple Sclerosis)

► Show Figures

Figure 1

13 pages, 1742 KiB

Open AccessArticle

Progressive Elevation of Store-Operated Calcium Entry-Associated Regulatory Factor (SARAF) and Calcium Pathway Dysregulation in Multiple Sclerosis

by Safa Taha, Muna Aljishi, Ameera Sultan, Moudi E. Al-Nashmi, Moiz Bakhiet, Salvatore Spicuglia and Mohamed Belhocine

Int. J. Mol. Sci. 2025, 26(10), 4520; https://doi.org/10.3390/ijms26104520 - 9 May 2025

Viewed by 218

Abstract

Multiple Sclerosis (MS) is a chronic autoimmune disorder characterized by demyelination and neuronal damage in the central nervous system. Dysregulation of calcium homeostasis, particularly through the Store-Operated Calcium Entry-Associated Regulatory Factor (SARAF), has been implicated in MS pathogenesis. This study investigated SARAF, STIM1, and Orai1 expression patterns and their relationship to calcium homeostasis in 45 Bahraini MS patients and 45 matched healthy controls using ELISA and real-time PCR analyses. MS patients showed significantly elevated serum SARAF levels in both early (192.26 ± 47.00 pg/mL) and late MS stages (341.47 ± 96.19 pg/mL) compared to controls (129.82 ± 30.82 pg/mL; p < 0.001. SARAF expressions were markedly increased in MS patients (3.829 ± 0.04422 vs. 1 ± 0; p < 0.0001), while STIM1 (0.4324 ± 0.01471) and ORAI1 (0.2963 ± 0.02156) expressions were significantly reduced compared to the controls (p < 0.0001). Intracellular calcium levels were notably elevated in both early and late MS stages. These findings suggest that the progressive elevation of SARAF, coupled with altered STIM1 and ORAI1 expression, may serve as potential biomarkers for MS progression and represent promising therapeutic targets. Full article

(This article belongs to the Special Issue Molecular Research and Treatment in Multiple Sclerosis)

► Show Figures

Figure 1

19 pages, 2035 KiB

Open AccessArticle

MIND Diet Impact on Multiple Sclerosis Patients: Biochemical Changes after Nutritional Intervention

by Ainoa Navarrete-Pérez, Sara Gómez-Melero, Begoña Mª Escribano, Alejandro Galvao-Carmona, Cristina Conde-Gavilán, Mª Ángeles Peña-Toledo, Noelia Villarrubia, Luisa Mª Villar, Isaac Túnez, Eduardo Agüera-Morales and Javier Caballero-Villarraso

Int. J. Mol. Sci. 2024, 25(18), 10009; https://doi.org/10.3390/ijms251810009 - 17 Sep 2024

Cited by 1 | Viewed by 2756

Abstract

There is substantial evidence supporting the neuroprotective effects of the MIND diet in neurodegenerative diseases like Parkinson’s and Alzheimer’s. Our aim was to evaluate the impact of a nutritional intervention (NI) with this diet on multiple sclerosis (MS) patients. The study was conducted in two stages. In the first stage, two groups were included: MS patients before the NI (group A) and healthy control subjects (group B). In this stage, groups (A) and (B) were compared (case–control study). In the second stage, group (A) was assessed after the NI, with comparisons made between baseline and final measurements (before-and-after study). In the case–control stage (baseline evaluation), we found significant differences in fatigue scores (p < 0.001), adherence to the MIND diet (p < 0.001), the serum levels of brain-derived neurotrophic factor (BDNF) (p < 0.001), and higher oxidative status in the MS group, with lower levels of reduced glutathione (p < 0.001), reduced/oxidised glutathione ratio (p < 0.001), and elevated levels of lipoperoxidation (p < 0.002) and 8-hydroxy-2′-deoxyguanosine (p < 0.025). The before-and-after intervention stage showed improvements in fatigue scores (p < 0.001) and physical quality-of-life scores (MSQOL-54) (p < 0.022), along with decreases in the serum levels of glial-derived neurotrophic factor (GDNF) (p < 0.041), lipoperoxidation (p < 0.046), and 8-hydroxy-2′-deoxyguanosine (p < 0.05). Consumption of the MIND diet is linked to clinical and biochemical improvement in MS patients. Full article

(This article belongs to the Special Issue Molecular Research and Treatment in Multiple Sclerosis)

► Show Figures

Figure 1

11 pages, 272 KiB

Open AccessArticle

CCR5 Δ32 and CTLA-4 +49 A/G Gene Polymorphisms and Interferon-β Treatment Response in Croatian and Slovenian Multiple Sclerosis Patients

by Jasna Nekić, Ivana Stanković Matić, Valentino Rački, Dolores Janko Labinac, Vladimira Vuletić, Miljenko Kapović, Smiljana Ristić, Borut Peterlin and Nada Starčević Čizmarević

Int. J. Mol. Sci. 2024, 25(13), 7412; https://doi.org/10.3390/ijms25137412 - 5 Jul 2024

Viewed by 1372

Abstract

The aim of the present study was to investigate the impact of CCR5 Δ32 and CTLA-4 polymorphisms on the response to IFN-β treatment in our cohort of MS patients from Croatia and Slovenia. Genomic DNA was obtained from 295 MS patients (230 female; 65 male) classified as responders (n = 173) and non-responders (n = 122) based on clinical criteria for treatment efficacy. Genotyping was performed via PCR/PCR-RFLP. No significant differences in the genotype/allele frequencies of CCR5Δ32 and CTLA-4 +49 A/G were detected between male responders and non-responders. A significantly higher prevalence (p = 0.039) of the CTLA-4 +49 AA genotype was found in female responders (42.1%) compared to non-responders (28.9%). Using multiple forward regression analysis, the CTLA-4 +49 AA genotype significantly predicted a positive response to IFN-β therapy in females (p = 0.011) and contributed to 4.5% of response variability. Furthermore, the combined presence of the CCR5Δ32 wtwt/CTLA-4 +49 AA genotype significantly predicted a positive response to treatment in females (p = 0.025). The age at disease onset, pretreatment relapse rate, and baseline EDSS score were not reliable predictors of treatment response in MS patients. Our results indicate that the presence of the CCR5Δ32 polymorphism was not associated with the response to IFN-β treatment, whereas the CTLA-4 +49 polymorphism showed a positive correlation with an optimal response in female patients. Full article

(This article belongs to the Special Issue Molecular Research and Treatment in Multiple Sclerosis)

Show export options Show export options

Select all

Export citation of selected articles as:

Displaying articles 1-4

Journal Menu

Journal Browser

Molecular Research and Treatment in Multiple Sclerosis

Share This Special Issue

Special Issue Editors

Special Issue Information

Keywords

Benefits of Publishing in a Special Issue

Published Papers (4 papers)

Research

Further Information

Guidelines

MDPI Initiatives

Follow MDPI